Implantable Sustained Release Device for Tumor Drug Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current intra-arterial drug delivery methods for cancer treatment face challenges in maintaining high local drug concentrations and prolonged exposure durations due to limitations in arterial blood flow and drug elimination rates, necessitating improved targeted drug delivery systems.

Innovation Solution

A biocompatible and bioresorbable implantable sustained release device is deployed in arteries to release chemotherapeutic agents over a prolonged period, utilizing a mesh with helical loops, fenestrated collapsible hollow shell, or folded sheath, coated with bioabsorbable polymers, to ensure sustained drug delivery to tumors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If intra-arterial drug delivery is used to achieve high local drug concentration, then tumor treatment efficacy is improved, but the duration of drug exposure is limited due to arterial blood flow rate and drug elimination rate

Engineering Contradiction:

Improvelocal drug concentrationVSAvoidduration of drug exposure

Core Design Contradiction:

Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The device is implanted in the artery before the full course of treatment, establishing a sustained release system that continuously delivers drug over time. The implantable structure is prepared in advance to provide prolonged exposure rather than relying on repeated bolus injections.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The device provides continuous drug release through its sustained release mechanism, maintaining constant drug delivery to the tumor site over an extended period. This continuous action overcomes the limitation of transient drug presence from conventional infusion methods.

Inventive Principle:

Principle #20Continuity of useful action

2Ease of operation

If conventional intravenous administration is used, then drug delivery is simple, but systemic toxicity occurs and first pass metabolism reduces efficacy

Engineering Contradiction:

Improvesimplicity of drug deliveryVSAvoidsystemic toxicity

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The device is positioned specifically in the tumor-fed artery to deliver drug locally to the tumor site. This localized delivery approach concentrates the therapeutic effect at the target while minimizing systemic circulation of the drug, thereby reducing systemic toxicity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The implantable device acts as an intermediary between the intravenous administration route and the tumor target. It captures the drug from the bloodstream and releases it sustainably at the tumor site, eliminating first-pass metabolism issues while maintaining ease of initial drug administration.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If low arterial blood flow rate is present to maintain high local drug level, then tumor treatment is improved, but drug delivery to the tumor is limited

Engineering Contradiction:

Improvelocal drug levelVSAvoiddrug delivery rate

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The device utilizes the existing arterial blood flow to deliver drug to the tumor site without requiring external pumping or high flow rates. The sustained release mechanism allows the device to self-regulate drug delivery, extracting drug from the flowing blood and releasing it at the tumor site passively.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The device changes the drug delivery parameters from flow-dependent bolus injection to flow-independent sustained release. By controlling the release rate through the device structure and material properties rather than relying on blood flow rate, it maintains effective drug levels despite low arterial flow.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The device achieves prolonged release of chemotherapeutic agents, maintaining effective drug concentrations for 1 to 6 months, enhancing treatment efficacy by ensuring consistent bioactive threshold exposure, and can be adapted for various tumor locations, including the dura mater and liver.

Implementation Method 1

release a chemotherapeutic agent for a prolonged period

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

bioabsorbable polymers

Methodology Applied

Scientific EffectBiodegradation: Decomposition (biological)

Data Source

PatentUS20240238226A1Implantable sustained release device and a method of use thereof

Publication Date: 2024.07.18 QURESHI ADNAN I

AI summary

A biocompatible and bioresorbable implantable device that is intended to be deployed in the arteries supplying the tumors through intra-arterial catheters and release a chemotherapeutic agent for a prolonged period into the branches of the artery to treat tumors. The implantable device may be a mesh with multiple helical loops, fenestrated collapsible hollow shell or spheroid, or folded sheath.